Clinical application of a OneDose™ MOSFET for skin dose measurements during internal mammary chain irradiation with high dose rate brachytherapy in carcinoma of the breast

Kinhikar, Rajesh; Sharma, Pramod Kumar; Tambe, Chandrashekhar M; Mahantshetty, Umesh; Sarin, Rajiv; Deshpande, Deepak D.; Shrivastava, Shyam Kishore

doi:10.1088/0031-9155/51/14/n01

Cited by 14 publications

(11 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A dose overestimation of 14% by the TPS was also observed by Mangold et al when PDR brachytherapy was used following the surgical treatment of breast cancer. 29 Kinhikar et al 45 reported that the TPS overestimated the skin dose by approximately 9% by comparing the calculated dose with MOSFET and TLD measurements. Readings taken at the posterior end of the rectal wall were greater in the presence of the empty volume, differing from the full rectum measurements by 22%-26%.…”

Section: Iiid Absorbed Dose In a Heterogeneous And Homogeneous Rectmentioning

confidence: 99%

The effect of rectal heterogeneity on wall dose in high dose rate brachytherapy

et al. 2008

View full text Add to dashboard Cite

When treating prostate cancer using high dose rate (HDR) brachytherapy, overdosing the rectal wall may lead to post-treatment rectal complications. An area of concern is related to how the rectal wall dose is calculated by treatment planning systems (TPSs). TPSs are used to calculate the dose delivered to the rectal wall, but they assume that the rectum is a water-equivalent homogeneous medium of infinite size and do not consider the effect that an air-filled "empty" rectal cavity would have on the dose absorbed along the rectal wall. The aim of this research is to quantify the effect that an air cavity has on the rectal wall dose, as its presence changes the backscatter conditions in the region. The MO Skin and RADFET dosimeters proved capable of measuring absolute dose with increasing distance from the HDR Ir-192 brachytherapy source. However, the anterior rectal wall doses measured by the MOSkin and RADFET in an empty rectal cavity were 14.7 +/- 0.2% and 13.7 +/- 0.6% lower than the dose measured in a homogeneous rectal phantom. Monte Carlo simulations corroborated the experimentally obtained results, reporting a -13.2 +/- 0.6% difference. The dose measured at the posterior wall of an empty rectal cavity was between 22% and 26% greater than the dose measured in a full rectal cavity. The heterogeneity of the rectal volume appears to have a significant effect on the rectal dose when compared to calculated rectal dose.

show abstract

Section: Iiid Absorbed Dose In a Heterogeneous And Homogeneous Rectmentioning

confidence: 99%

The effect of rectal heterogeneity on wall dose in high dose rate brachytherapy

et al. 2008

View full text Add to dashboard Cite

show abstract

“…32,33,41 Noninvasive detector positioning far from the source, e.g., on the skin, make the measurements insensitive to error detection because of low signal and difficulties to know precisely the relation between the source(s) and detector(s). IVD on skin is of relevance during the treatment of breast cancer [42][43][44] since the skin is an OAR close to the treated volume and has significant dose calculation uncertainties. 45 The practice of using IVD varies considerably among countries.…”

Section: Current Clinical Practicementioning

confidence: 99%

In vivo dosimetry in brachytherapy

et al. 2013

View full text Add to dashboard Cite

In vivo dosimetry (IVD) has been used in brachytherapy (BT) for decades with a number of different detectors and measurement technologies. However, IVD in BT has been subject to certain difficulties and complexities, in particular due to challenges of the high-gradient BT dose distribution and the large range of dose and dose rate. Due to these challenges, the sensitivity and specificity toward error detection has been limited, and IVD has mainly been restricted to detection of gross errors. Given these factors, routine use of IVD is currently limited in many departments. Although the impact of potential errors may be detrimental since treatments are typically administered in large fractions and with high-gradient-dose-distributions, BT is usually delivered without independent verification of the treatment delivery. This Vision 20/20 paper encourages improvements within BT safety by developments of IVD into an effective method of independent treatment verification.

show abstract

“…[4] The drawbacks of the dosimeters such as destructive technique, annealing process[56] and ineffectualness in reestimating the dose with thermoluminescent dosimeters, reduced lifetime with metal oxide semiconductor field effect transistors (MOSFETs)[78] necessity for corrective actions required with diode,[910] cumbersome measurements with cables (MOSFET, diodes),[11] and non-suitability in patient dosimetry with plane-parallel ionization chamber (gold standard in electron beam dosimetry)[12] persist the necessity to explore new dosimetric method for dosimetric verification. [13] The dosimeters that are based on the luminescence properties of solids are highly suitable for in vivo and in-phantom measurements as they are available in small sizes providing high spatial resolution and wider dose range coverage with high precision. [141516] Optically stimulated luminescence dosimeter (OSLD) has been introduced into radiation dosimetry, yet it is well known as a suitable dosimeter in space dosimetry and personal dosimetry over a decade.…”

Section: Introductionmentioning

confidence: 99%

Response of nanodot optically stimulated luminescence dosimeters to therapeutic electron beams

et al. 2017

View full text Add to dashboard Cite

Response of Al2O3:C-based nanoDot optically stimulated luminescence (OSL) dosimeter was studied for the dosimetry of 6, 9, 12, 16, and 20 MeV therapeutic electron beams. With reference to ionization chamber, no change in the response was observed with the change in the energy of electron beams for the field size from 6 cm × 6 cm to 25 cm × 25 cm, dose rates from 100 MU/min to 600 MU/min, and the linearity in the response up to 300 cGy. The fading of the transient signal was higher for 20 MeV electron beam than that of 6 MeV electron beam by about 5% as compared to value at 20 min after irradiation. The depletion of OSL signal per readout in 200 successive readouts was also found to change with dose and energy of electron beam from 6 MeV (9% and 12% per readout at 2 and 10 Gy, respectively) to 20 MeV (9% and 16% at 2 and 10 Gy, respectively). The OSL sensitivity changed in the range from 2% to 6% with accumulated doses from 2 to 8 Gy and with electron energy from 6 to 20 MeV, but the sensitivity could be reset using an optical annealing treatment. Although negligible fading for postirradiation storage from 20 min to several months, acceptable precision and linearity in the desired range, and high reproducibility makes nanoDot dosimeters very attractive for the dosimetry of therapeutic electron beams, a note should be made for changes in sensitivity at doses beyond 2 Gy and electron beams energy dependence in reuse, short-term fading, and signal depletion on repeated readout.

show abstract

Clinical application of a OneDose™ MOSFET for skin dose measurements during internal mammary chain irradiation with high dose rate brachytherapy in carcinoma of the breast

Cited by 14 publications

References 8 publications

The effect of rectal heterogeneity on wall dose in high dose rate brachytherapy

The effect of rectal heterogeneity on wall dose in high dose rate brachytherapy

In vivo dosimetry in brachytherapy

Response of nanodot optically stimulated luminescence dosimeters to therapeutic electron beams

Contact Info

Product

Resources

About